Murine study reveals mast cells promote venous clot stability and pulmonary thrombo-inflammation during sepsis, indicating mast cell activity impairs clot breakdown.
Venous thrombo-embolism is a serious complication of sepsis despite standard thromboprophylaxis. Mast cells (MCs) promote deep vein thrombosis (DVT) in sterile murine models, but their contribution during sepsis remains unknown. We explored the role of MCs in DVT in lipopolysaccharide (LPS)-induced sepsis in mice. We show that LPS treatment does not alter DVT prevalence or size in control C57BL/6 mice but increases intra-thrombus inflammatory mediators including interleukin-1b (IL-1β) and citrullinated histone 3 (CitH3), a hallmark of neutrophil extracellular traps (NETs). MC ablation (KITW-sh mice) protected animals from sterile DVT for up to one week, while in endotoxemia settings, KITW-sh mice produced thrombi similar to controls. Thrombi from KITW-sh mice were more susceptible to lysis by a combination of tissue plasminogen activator and DNase I and contained less CitH3 than controls. Septic DVT exacerbated pulmonary thrombo-inflammation characterized by large fibrin deposits and high levels of CitH3 and IL-1b in control but not KITW-sh mice. MC deficiency during septic DVT was associated with decreased plasma angiopoietin-2 levels, suggesting improved endothelial stability and reduced vascular inflammation. Thus, in septic conditions, MCs are dispensable for thrombus initiation but promote NET-rich thrombus stability, resistance to lysis and pulmonary thrombo-inflammation, the major life-threatening complication of DVT.
No takes yet. Share an insight, caveat, or question.
Rayes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: